newsfilter
← Latest News
PR Newswire·

Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis

Study will evaluate drug's potential neuro-restorative mechanism(s) of action for improving synaptic health and cognitive function in MS patients NEW YORK, July 19, 2023 /PRNewswire/ -- Synaptogenix, Inc.